Asset Details
Do you wish to reserve the book?
Smoking‐independent DNA methylation markers for lung cancer risk: External validation in a large population‐based cohort study
Hey, we have placed the reservation for you!
By the way, why not check out events that you can attend while you pick your title.
Oops! Something went wrong.
Looks like we were not able to place the reservation. Kindly try again later.
Are you sure you want to remove the book from the shelf?
Smoking‐independent DNA methylation markers for lung cancer risk: External validation in a large population‐based cohort study
Do you wish to request the book?
Smoking‐independent DNA methylation markers for lung cancer risk: External validation in a large population‐based cohort study
Please be aware that the book you have requested cannot be checked out. If you would like to checkout this book, you can reserve another copy
We have requested the book for you!
Your request is successful and it will be processed during the Library working hours. Please check the status of your request in My Requests.
Oops! Something went wrong.
Looks like we were not able to place your request. Kindly try again later.
Journal Article
Smoking‐independent DNA methylation markers for lung cancer risk: External validation in a large population‐based cohort study
2025
Overview
Smoking‐associated epigenetic changes have been linked to lung cancer (LC) risk; however, the role of epigenetic alterations independent of smoking is yet to be fully understood. This study aimed to validate 16 previously reported CpG sites that are independent of smoking yet associated with LC risk within a population‐based prospective cohort. Using the Infinium Methylation EPIC BeadChip kit or the Infinium HumanMethylation450K BeadChip Assay, DNA methylation (DNAm) in whole blood was assessed in four subsets (n = 736, 1027, 997, and 312) of a population‐based cohort from Germany. The DNAm levels of the 16 smoking‐independent CpG sites were analyzed. Hazard ratios (HRs) and their 95% confidence intervals (95% CIs) were calculated to assess associations of DNAm at the 16 CpG sites with LC risk, adjusting for multiple covariates, including smoking habits and a smoking‐associated DNAm score. Over 17 years of follow‐up, a total of 199 LCs were observed. Among the 16 CpGs, cg02211449 showed a negative association with LC risk (HR [95% CI] per SD increase, = 0.70 [0.63–0.78]), while cg11385536 (1.04 [1.01–1.07]), cg09736286 (1.64 [1.10–2.44]), cg19907023 (1.64 [1.01–2.66]), and cg22032485 (1.52 [1.04–2.21]) displayed positive associations with LC risk. Five of the 16 suggested smoking‐independent CpGs could be externally validated as predictors of LC risk. Further research should address their potential contribution to enhanced LC risk stratification. This study validated 16 CpG sites independent of smoking and their association with lung cancer (LC) risk in a population‐based cohort from Germany. Among these, five CpGs were significantly associated with LC risk, suggesting their potential utility in enhancing LC risk prediction beyond smoking‐related factors.
Publisher
John Wiley & Sons, Inc,John Wiley and Sons Inc
Subject
